

WEBVTT

NOTE duration:"00:17:09"

NOTE recognizability:0.878

NOTE language:en-us

NOTE Confidence: 0.870504936

00:00:00.000 --> 00:00:02.115 We're good. OK, OK, great.

NOTE Confidence: 0.870504936

00:00:02.115 --> 00:00:04.230 There are times a charm.

NOTE Confidence: 0.870504936

00:00:04.230 --> 00:00:07.029 So uhm so uh thanks it's been great to

NOTE Confidence: 0.870504936

00:00:07.029 --> 00:00:10.085 hear some of the talks from the morning I.

NOTE Confidence: 0.870504936

00:00:10.090 --> 00:00:11.385 I think one of the things I

NOTE Confidence: 0.870504936

00:00:11.385 --> 00:00:12.599 was going to say and I'll,

NOTE Confidence: 0.870504936

00:00:12.600 --> 00:00:14.528 I'll make mine a little bit more informal.

NOTE Confidence: 0.870504936

00:00:14.530 --> 00:00:16.231 So really, if people want to ask

NOTE Confidence: 0.870504936

00:00:16.231 --> 00:00:17.550 questions even in in between,

NOTE Confidence: 0.870504936

00:00:17.550 --> 00:00:18.582 that'll be fine.

NOTE Confidence: 0.870504936

00:00:18.582 --> 00:00:21.454 One of the things that we did in

NOTE Confidence: 0.870504936

00:00:21.454 --> 00:00:24.128 inviting our trial pies was make a

NOTE Confidence: 0.870504936

00:00:24.128 --> 00:00:26.617 request today that they simply didn't

NOTE Confidence: 0.870504936

00:00:26.617 --> 00:00:29.324 talk about the protocol and the design.

NOTE Confidence: 0.870504936

00:00:29.324 --> 00:00:31.196 One. I think a lot of us have.

NOTE Confidence: 0.870504936

00:00:31.200 --> 00:00:32.880 Heard that that you know might

NOTE Confidence: 0.870504936

00:00:32.880 --> 00:00:34.418 be a little bit, you know,

NOTE Confidence: 0.870504936

00:00:34.418 --> 00:00:35.881 but what we thought we could do

NOTE Confidence: 0.870504936

00:00:35.881 --> 00:00:37.647 and I think this is an originally

NOTE Confidence: 0.870504936

00:00:37.647 --> 00:00:39.119 Lauren Sansing's idea to you know,

NOTE Confidence: 0.870504936

00:00:39.120 --> 00:00:41.010 to ask him a little bit about

NOTE Confidence: 0.870504936

00:00:41.010 --> 00:00:43.160 the back story you know and and

NOTE Confidence: 0.870504936

00:00:43.160 --> 00:00:44.755 and some other questions about

NOTE Confidence: 0.870504936

00:00:44.755 --> 00:00:46.860 that you don't always hear about,

NOTE Confidence: 0.870504936

00:00:46.860 --> 00:00:49.849 so I thought I would very much

NOTE Confidence: 0.870504936

00:00:49.849 --> 00:00:51.950 do that for aspire.

NOTE Confidence: 0.870504936

00:00:51.950 --> 00:00:53.330 These aren't the things you would

NOTE Confidence: 0.870504936

00:00:53.330 --> 00:00:54.899 find in the protocol or the lead

NOTE Confidence: 0.870504936

00:00:54.899 --> 00:00:56.299 up that that might be relevant when

NOTE Confidence: 0.870504936

00:00:56.350 --> 00:00:57.928 you're thinking about your own trial,

NOTE Confidence: 0.870504936

00:00:57.930 --> 00:00:59.268 because all of these things they

NOTE Confidence: 0.870504936

00:00:59.268 --> 00:01:00.709 always do have a back story.

NOTE Confidence: 0.870504936

00:01:00.710 --> 00:01:01.904 Every little detail,

NOTE Confidence: 0.870504936

00:01:01.904 --> 00:01:04.292 and the first thing really is,

NOTE Confidence: 0.870504936

00:01:04.300 --> 00:01:05.164 you know the waste.

NOTE Confidence: 0.870504936

00:01:05.164 --> 00:01:06.754 One of the things that I think

NOTE Confidence: 0.870504936

00:01:06.754 --> 00:01:08.224 about at the beginning of really

NOTE Confidence: 0.870504936

00:01:08.224 --> 00:01:10.033 most of the projects I started is

NOTE Confidence: 0.870504936

00:01:10.033 --> 00:01:11.652 just don't say the choice of team

NOTE Confidence: 0.870504936

00:01:11.652 --> 00:01:13.344 but just the team that you either

NOTE Confidence: 0.870504936

00:01:13.344 --> 00:01:15.038 choose or that you end up working

NOTE Confidence: 0.870504936

00:01:15.094 --> 00:01:16.578 with and a little bit of both.

NOTE Confidence: 0.870504936

00:01:16.580 --> 00:01:19.364 And you know I want to just mention

NOTE Confidence: 0.870504936

00:01:19.364 --> 00:01:21.456 a couple of people, of course.

NOTE Confidence: 0.870504936

00:01:21.456 --> 00:01:23.560 There are a lot of folks that are  
NOTE Confidence: 0.870504936

00:01:23.624 --> 00:01:25.359 involved in a clinical trial,  
NOTE Confidence: 0.870504936

00:01:25.360 --> 00:01:26.017 but you know,  
NOTE Confidence: 0.870504936

00:01:26.017 --> 00:01:27.798 one of the things that I would say  
NOTE Confidence: 0.870504936

00:01:27.798 --> 00:01:29.350 I think is as many of you know,  
NOTE Confidence: 0.870504936

00:01:29.350 --> 00:01:32.977 I'm a critical care neurologist and you know,  
NOTE Confidence: 0.870504936

00:01:32.977 --> 00:01:35.070 here I was trying to think about  
NOTE Confidence: 0.870504936

00:01:35.143 --> 00:01:37.488 proposing a stroke prevention trial,  
NOTE Confidence: 0.870504936

00:01:37.490 --> 00:01:39.282 so I thought that you know people  
NOTE Confidence: 0.870504936

00:01:39.282 --> 00:01:41.628 might laugh and find that a little bit funny.  
NOTE Confidence: 0.870504936

00:01:41.630 --> 00:01:43.510 Doing stroke prevention is something  
NOTE Confidence: 0.870504936

00:01:43.510 --> 00:01:46.418 that I always wanted to do ever since  
NOTE Confidence: 0.870504936

00:01:46.418 --> 00:01:48.338 fellowship and it just happened to  
NOTE Confidence: 0.870504936

00:01:48.338 --> 00:01:50.372 be that my clinical interests were  
NOTE Confidence: 0.870504936

00:01:50.372 --> 00:01:52.796 mostly in sort of acute neurology.  
NOTE Confidence: 0.870504936

00:01:52.800 --> 00:01:56.050 So a few years ago I before aspire,

NOTE Confidence: 0.870504936

00:01:56.050 --> 00:01:58.395 you know where it's nice at Yale.

NOTE Confidence: 0.870504936

00:01:58.400 --> 00:02:00.176 We have sabbaticals every so often

NOTE Confidence: 0.870504936

00:02:00.176 --> 00:02:03.204 and so I I had a sabbatical and I

NOTE Confidence: 0.870504936

00:02:03.204 --> 00:02:05.215 used that experience to really think

NOTE Confidence: 0.870504936

00:02:05.215 --> 00:02:07.420 about how to design and think about.

NOTE Confidence: 0.870504936

00:02:07.420 --> 00:02:07.934 You know,

NOTE Confidence: 0.870504936

00:02:07.934 --> 00:02:09.476 doing a prevention trial in a

NOTE Confidence: 0.870504936

00:02:09.476 --> 00:02:10.948 disease that I did know something

NOTE Confidence: 0.870504936

00:02:10.948 --> 00:02:12.667 about and was sort of passionate

NOTE Confidence: 0.870504936

00:02:12.667 --> 00:02:14.485 about and there was no interest,

NOTE Confidence: 0.870504936

00:02:14.490 --> 00:02:15.300 real hemorrhage.

NOTE Confidence: 0.870504936

00:02:15.300 --> 00:02:18.540 And in doing that one of the first

NOTE Confidence: 0.870504936

00:02:18.629 --> 00:02:21.923 things that I did was reach out to a

NOTE Confidence: 0.870504936

00:02:21.923 --> 00:02:24.355 colleague who was many of you know who,

NOTE Confidence: 0.870504936

00:02:24.360 --> 00:02:25.182 Monica Mellow.

NOTE Confidence: 0.870504936

00:02:25.182 --> 00:02:27.237 As my copii at Cornell,  
NOTE Confidence: 0.870504936

00:02:27.240 --> 00:02:29.242 and I say this with great respect  
NOTE Confidence: 0.870504936

00:02:29.242 --> 00:02:30.699 to everyone on the call.  
NOTE Confidence: 0.870504936

00:02:30.700 --> 00:02:31.396 But you know,  
NOTE Confidence: 0.870504936

00:02:31.396 --> 00:02:33.020 one of the reasons we reached out  
NOTE Confidence: 0.9332078

00:02:33.072 --> 00:02:34.524 and I started working with him  
NOTE Confidence: 0.9332078

00:02:34.524 --> 00:02:36.452 was one because of his, you know,  
NOTE Confidence: 0.9332078

00:02:36.452 --> 00:02:38.232 deep and recent experience in  
NOTE Confidence: 0.9332078

00:02:38.232 --> 00:02:40.029 getting Arcadia off the ground.  
NOTE Confidence: 0.9332078

00:02:40.030 --> 00:02:41.406 Even though it was  
NOTE Confidence: 0.9332078

00:02:41.406 --> 00:02:42.438 hemorrhaging ischemic strokes.  
NOTE Confidence: 0.9332078

00:02:42.440 --> 00:02:44.580 Some of the questions and  
NOTE Confidence: 0.9332078

00:02:44.580 --> 00:02:45.864 practical interventions were  
NOTE Confidence: 0.9332078

00:02:45.864 --> 00:02:48.288 going to be very much the same,  
NOTE Confidence: 0.9332078

00:02:48.290 --> 00:02:50.626 and also because I really thought from our  
NOTE Confidence: 0.9332078

00:02:50.626 --> 00:02:52.778 generation he was really one of the nicest,

NOTE Confidence: 0.9332078

00:02:52.780 --> 00:02:54.505 smartest people in the field

NOTE Confidence: 0.9332078

00:02:54.505 --> 00:02:56.870 and so being able to capture.

NOTE Confidence: 0.9332078

00:02:56.870 --> 00:02:58.448 Both of those things you know

NOTE Confidence: 0.9332078

00:02:58.448 --> 00:03:00.260 was was a great opportunity.

NOTE Confidence: 0.9332078

00:03:00.260 --> 00:03:01.748 The other thing that ended up

NOTE Confidence: 0.9332078

00:03:01.748 --> 00:03:03.160 playing a big role for me.

NOTE Confidence: 0.9332078

00:03:03.160 --> 00:03:04.588 We've had a lot of folks

NOTE Confidence: 0.9332078

00:03:04.588 --> 00:03:05.540 in our steering committee,

NOTE Confidence: 0.9332078

00:03:05.540 --> 00:03:08.178 but just being here at Yale was

NOTE Confidence: 0.9332078

00:03:08.178 --> 00:03:09.568 being close to Walt Kernan.

NOTE Confidence: 0.9332078

00:03:09.570 --> 00:03:10.818 And as all of you know,

NOTE Confidence: 0.9332078

00:03:10.820 --> 00:03:11.877 I mean, I think many of you,

NOTE Confidence: 0.9332078

00:03:11.880 --> 00:03:13.450 Karen and others were involved

NOTE Confidence: 0.9332078

00:03:13.450 --> 00:03:14.706 in the IRIS trial,

NOTE Confidence: 0.9332078

00:03:14.710 --> 00:03:16.859 which was really only one of the

NOTE Confidence: 0.9332078

00:03:16.859 --> 00:03:19.632 one of the few sort of successful  
NOTE Confidence: 0.9332078

00:03:19.632 --> 00:03:21.852 prevention trials in NIH history,  
NOTE Confidence: 0.9332078

00:03:21.860 --> 00:03:24.070 at least by efficacy outcome,  
NOTE Confidence: 0.9332078

00:03:24.070 --> 00:03:25.015 and you know,  
NOTE Confidence: 0.9332078

00:03:25.015 --> 00:03:27.220 to have that experience was very helpful.  
NOTE Confidence: 0.9332078

00:03:27.220 --> 00:03:29.388 To have in hand and thinking about the  
NOTE Confidence: 0.9332078

00:03:29.388 --> 00:03:31.450 concept but even big picture questions,  
NOTE Confidence: 0.9332078

00:03:31.450 --> 00:03:33.004 I remember one of the things that  
NOTE Confidence: 0.9332078

00:03:33.004 --> 00:03:34.717 Walt asked me at the beginning was,  
NOTE Confidence: 0.9332078

00:03:34.720 --> 00:03:36.968 you know, do you really want to commit  
NOTE Confidence: 0.9332078

00:03:36.968 --> 00:03:38.937 potentially 7 to 10 years of your life?  
NOTE Confidence: 0.9332078

00:03:38.940 --> 00:03:39.488 You know,  
NOTE Confidence: 0.9332078

00:03:39.488 --> 00:03:41.680 before you embark on an endeavor like that,  
NOTE Confidence: 0.9332078

00:03:41.680 --> 00:03:42.976 you gotta really think about that.  
NOTE Confidence: 0.9332078

00:03:42.980 --> 00:03:44.830 So that was very helpful.  
NOTE Confidence: 0.9332078

00:03:44.830 --> 00:03:47.486 The 4th person I haven't put here and

NOTE Confidence: 0.9332078

00:03:47.486 --> 00:03:49.480 that's because she's oftentimes pretty

NOTE Confidence: 0.9332078

00:03:49.480 --> 00:03:51.994 humble about these kinds of things.

NOTE Confidence: 0.9332078

00:03:52.000 --> 00:03:53.180 And it is, you know,

NOTE Confidence: 0.9332078

00:03:53.180 --> 00:03:54.710 if you go to Google pictures,

NOTE Confidence: 0.9332078

00:03:54.710 --> 00:03:56.897 you really cannot even find a picture of her.

NOTE Confidence: 0.9332078

00:03:56.900 --> 00:03:57.938 I mean, it's.

NOTE Confidence: 0.9332078

00:03:57.938 --> 00:03:58.976 Really quite remarkable,

NOTE Confidence: 0.9332078

00:03:58.980 --> 00:04:01.437 and that and that's Catherine Visco Lee.

NOTE Confidence: 0.9332078

00:04:01.440 --> 00:04:02.982 So Catherine Viscol is some of

NOTE Confidence: 0.9332078

00:04:02.982 --> 00:04:04.802 you know that this is the picture

NOTE Confidence: 0.9332078

00:04:04.802 --> 00:04:06.524 that she did send me of herself,

NOTE Confidence: 0.9332078

00:04:06.530 --> 00:04:08.778 which in some ways you know it's it's

NOTE Confidence: 0.9332078

00:04:08.778 --> 00:04:11.219 not not not an inappropriate picture.

NOTE Confidence: 0.9332078

00:04:11.220 --> 00:04:12.336 I'll tell you.

NOTE Confidence: 0.9332078

00:04:12.336 --> 00:04:13.080 But Catherine,

NOTE Confidence: 0.9332078

00:04:13.080 --> 00:04:15.824 this Coley is is not a clinician,  
NOTE Confidence: 0.9332078

00:04:15.830 --> 00:04:18.210 but actually has been involved  
NOTE Confidence: 0.9332078

00:04:18.210 --> 00:04:19.638 in stroke investigation.  
NOTE Confidence: 0.9332078

00:04:19.640 --> 00:04:20.200 You know,  
NOTE Confidence: 0.9332078

00:04:20.200 --> 00:04:22.820 for many many years and I I don't know  
NOTE Confidence: 0.9332078

00:04:22.820 --> 00:04:24.983 if people at Yale even know this.  
NOTE Confidence: 0.852808542

00:04:27.020 --> 00:04:28.286 Sort of having some of these  
NOTE Confidence: 0.852808542

00:04:28.286 --> 00:04:30.466 slides out of order, what's up?  
NOTE Confidence: 0.852808542

00:04:30.466 --> 00:04:33.138 But you know Catherine.  
NOTE Confidence: 0.852808542

00:04:33.140 --> 00:04:35.332 Actually, you know has a CV in some  
NOTE Confidence: 0.852808542

00:04:35.332 --> 00:04:37.531 ways that you know some stroke  
NOTE Confidence: 0.852808542

00:04:37.531 --> 00:04:39.740 investigators would never have, even at  
NOTE Confidence: 0.852808542

00:04:39.740 --> 00:04:41.910 over the course of their whole career.  
NOTE Confidence: 0.852808542

00:04:41.910 --> 00:04:44.458 And you know she happened to have  
NOTE Confidence: 0.852808542

00:04:44.458 --> 00:04:46.429 this rich experience in thinking  
NOTE Confidence: 0.852808542

00:04:46.429 --> 00:04:48.853 about not just conducting the trial,

NOTE Confidence: 0.852808542

00:04:48.860 --> 00:04:51.260 but analyzing it, reporting it

NOTE Confidence: 0.852808542

00:04:51.260 --> 00:04:53.660 really doing everything from A-Z.

NOTE Confidence: 0.852808542

00:04:53.660 --> 00:04:55.820 Not only in these studies that you see here,

NOTE Confidence: 0.852808542

00:04:55.820 --> 00:04:57.080 but all still in the iris.

NOTE Confidence: 0.852808542

00:04:57.080 --> 00:05:01.130 Trial and, uh, so that you know, working.

NOTE Confidence: 0.852808542

00:05:01.130 --> 00:05:04.000 I think with this team from the

NOTE Confidence: 0.852808542

00:05:04.000 --> 00:05:06.040 beginning was just as much I,

NOTE Confidence: 0.852808542

00:05:06.040 --> 00:05:08.434 I think as important as the fundamental

NOTE Confidence: 0.852808542

00:05:08.434 --> 00:05:10.060 sort of scientific question.

NOTE Confidence: 0.852808542

00:05:10.060 --> 00:05:11.338 So I I just wanted to.

NOTE Confidence: 0.852808542

00:05:11.340 --> 00:05:12.999 I think this is obvious to everyone,

NOTE Confidence: 0.852808542

00:05:13.000 --> 00:05:14.680 but just to give a couple of

NOTE Confidence: 0.852808542

00:05:14.680 --> 00:05:16.520 pieces for how this came together,

NOTE Confidence: 0.852808542

00:05:16.520 --> 00:05:18.456 I think it's a critical part of how

NOTE Confidence: 0.852808542

00:05:18.456 --> 00:05:20.239 the trial concepts come together.

NOTE Confidence: 0.852808542

00:05:20.240 --> 00:05:20.694 You know,  
NOTE Confidence: 0.852808542

00:05:20.694 --> 00:05:22.510 in that context what I would say is,  
NOTE Confidence: 0.852808542

00:05:22.510 --> 00:05:24.390 and there are a lot of people I.  
NOTE Confidence: 0.852808542

00:05:24.390 --> 00:05:26.298 I'm just highlighting a few here  
NOTE Confidence: 0.852808542

00:05:26.298 --> 00:05:28.873 to make a point and make a point  
NOTE Confidence: 0.852808542

00:05:28.873 --> 00:05:30.418 in the context of aspire.  
NOTE Confidence: 0.852808542

00:05:30.420 --> 00:05:32.250 You know, when we were designing,  
NOTE Confidence: 0.852808542

00:05:32.250 --> 00:05:34.007 and as we've been conducting this study,  
NOTE Confidence: 0.852808542

00:05:34.010 --> 00:05:34.982 we've been thinking about  
NOTE Confidence: 0.852808542

00:05:34.982 --> 00:05:36.197 a lot of different things.  
NOTE Confidence: 0.852808542

00:05:36.200 --> 00:05:37.306 As you'll hear about in a minute,  
NOTE Confidence: 0.852808542

00:05:37.310 --> 00:05:39.144 you know what are the right outcomes?  
NOTE Confidence: 0.852808542

00:05:39.150 --> 00:05:43.670 What can we learn about aspire beyond aspire?  
NOTE Confidence: 0.852808542

00:05:43.670 --> 00:05:45.648 You know what are the relevant  
NOTE Confidence: 0.852808542

00:05:45.648 --> 00:05:48.336 outcomes beyond our top line outcomes,  
NOTE Confidence: 0.852808542

00:05:48.340 --> 00:05:50.516 and you can see here, you know,

NOTE Confidence: 0.852808542

00:05:50.516 --> 00:05:52.728 Lauren Gaido, Alessandro Biffi.

NOTE Confidence: 0.852808542

00:05:52.730 --> 00:05:54.580 I mean they've all had, I think,

NOTE Confidence: 0.852808542

00:05:54.580 --> 00:05:56.290 really key pieces of input into

NOTE Confidence: 0.852808542

00:05:56.290 --> 00:05:58.488 that and really unique perspectives.

NOTE Confidence: 0.852808542

00:05:58.490 --> 00:05:59.830 You know, we didn't choose,

NOTE Confidence: 0.852808542

00:05:59.830 --> 00:06:01.456 but you know,

NOTE Confidence: 0.852808542

00:06:01.456 --> 00:06:05.481 the current chair of the DSMB is Clark Haley.

NOTE Confidence: 0.852808542

00:06:05.481 --> 00:06:07.023 So as many of you know,

NOTE Confidence: 0.852808542

00:06:07.030 --> 00:06:09.172 Clark Haley was very involved in the

NOTE Confidence: 0.852808542

00:06:09.172 --> 00:06:11.756 leadership of the original NINDS TPA trials,

NOTE Confidence: 0.852808542

00:06:11.756 --> 00:06:14.430 and it turns out that these historical

NOTE Confidence: 0.852808542

00:06:14.499 --> 00:06:17.565 things become relevant because you know what?

NOTE Confidence: 0.852808542

00:06:17.570 --> 00:06:19.740 For in a different context,

NOTE Confidence: 0.852808542

00:06:19.740 --> 00:06:21.624 when they were thinking about when

NOTE Confidence: 0.852808542

00:06:21.624 --> 00:06:23.908 they were looking at TPA and having

NOTE Confidence: 0.852808542

00:06:23.908 --> 00:06:25.513 those very early DSMB meetings  
NOTE Confidence: 0.852808542

00:06:25.520 --> 00:06:28.090 for the NDS TPA trial,  
NOTE Confidence: 0.852808542

00:06:28.090 --> 00:06:30.526 they really had to think about this  
NOTE Confidence: 0.852808542

00:06:30.526 --> 00:06:32.589 balance of efficacy and hemorrhage,  
NOTE Confidence: 0.852808542

00:06:32.590 --> 00:06:34.840 bleeding and clotting in a very.  
NOTE Confidence: 0.852808542

00:06:34.840 --> 00:06:35.390 Sort of,  
NOTE Confidence: 0.852808542

00:06:35.390 --> 00:06:35.940 you know,  
NOTE Confidence: 0.852808542

00:06:35.940 --> 00:06:37.937 in an environment where they didn't really  
NOTE Confidence: 0.852808542

00:06:37.937 --> 00:06:39.988 know that much from a clinical context,  
NOTE Confidence: 0.852808542

00:06:39.990 --> 00:06:43.616 and without you know sharing any sort  
NOTE Confidence: 0.852808542

00:06:43.616 --> 00:06:46.559 of insight information from the trial,  
NOTE Confidence: 0.852808542

00:06:46.560 --> 00:06:48.330 I think everybody would understand that.  
NOTE Confidence: 0.852808542

00:06:48.330 --> 00:06:50.374 You know when you're thinking about aspire,  
NOTE Confidence: 0.852808542

00:06:50.380 --> 00:06:51.600 not just in the design,  
NOTE Confidence: 0.852808542

00:06:51.600 --> 00:06:54.001 but as the study goes along and  
NOTE Confidence: 0.852808542

00:06:54.001 --> 00:06:56.266 people start having endpoints clotting

NOTE Confidence: 0.852808542

00:06:56.266 --> 00:06:58.598 endpoints or hemorrhaging points.

NOTE Confidence: 0.852808542

00:06:58.600 --> 00:07:00.679 These issues really come to the fore.

NOTE Confidence: 0.852808542

00:07:00.680 --> 00:07:02.828 I'll give you one concrete example.

NOTE Confidence: 0.852808542

00:07:02.830 --> 00:07:05.174 Oftentimes in a trial like this people will.

NOTE Confidence: 0.852808542

00:07:05.180 --> 00:07:07.360 Think about having a hemorrhage

NOTE Confidence: 0.852808542

00:07:07.360 --> 00:07:09.104 as a safety outcome.

NOTE Confidence: 0.852808542

00:07:09.110 --> 00:07:12.182 Well, you could ask why, why should it?

NOTE Confidence: 0.852808542

00:07:12.182 --> 00:07:13.118 Why shouldn't hemorrhage only

NOTE Confidence: 0.852808542

00:07:13.118 --> 00:07:14.200 be a safety outcome?

NOTE Confidence: 0.852808542

00:07:14.200 --> 00:07:16.120 That's a that's if you think

NOTE Confidence: 0.852808542

00:07:16.120 --> 00:07:17.780 about safety as active harm.

NOTE Confidence: 0.852808542

00:07:17.780 --> 00:07:20.114 But if you think about ischemic

NOTE Confidence: 0.852808542

00:07:20.114 --> 00:07:21.670 stroke as sort of

NOTE Confidence: 0.8698586575

00:07:21.752 --> 00:07:24.926 passive harm or passive safety endpoint,

NOTE Confidence: 0.8698586575

00:07:24.930 --> 00:07:26.640 then then ischaemia is can also

NOTE Confidence: 0.8698586575

00:07:26.640 --> 00:07:28.310 be considered a safety endpoint,  
NOTE Confidence: 0.8698586575

00:07:28.310 --> 00:07:29.930 not just an efficacy endpoint.  
NOTE Confidence: 0.8698586575

00:07:29.930 --> 00:07:31.120 And believe it or not,  
NOTE Confidence: 0.8698586575

00:07:31.120 --> 00:07:32.677 some of these kinds of issues, really,  
NOTE Confidence: 0.8698586575

00:07:32.677 --> 00:07:34.966 as we've learned during the course of  
NOTE Confidence: 0.8698586575

00:07:34.966 --> 00:07:37.116 the trial, they're not completely baked.  
NOTE Confidence: 0.8698586575

00:07:37.116 --> 00:07:39.874 They really are something that you know.  
NOTE Confidence: 0.8698586575

00:07:39.874 --> 00:07:41.200 Requires ongoing conversation,  
NOTE Confidence: 0.8698586575

00:07:41.200 --> 00:07:44.119 so it's been helpful to get all  
NOTE Confidence: 0.8698586575

00:07:44.119 --> 00:07:45.370 these different perspectives.  
NOTE Confidence: 0.8698586575

00:07:45.370 --> 00:07:47.066 Uhm, choice of drug.  
NOTE Confidence: 0.8698586575

00:07:47.066 --> 00:07:49.186 So what really happens when  
NOTE Confidence: 0.8698586575

00:07:49.186 --> 00:07:51.408 you think about the drug?  
NOTE Confidence: 0.8698586575

00:07:51.410 --> 00:07:52.722 Well, I'll tell you.  
NOTE Confidence: 0.8698586575

00:07:52.722 --> 00:07:53.706 First of all,  
NOTE Confidence: 0.8698586575

00:07:53.710 --> 00:07:56.030 you know we went to we went to science right?

NOTE Confidence: 0.8698586575

00:07:56.030 --> 00:07:58.028 And we went to the history that we had.

NOTE Confidence: 0.8698586575

00:07:58.030 --> 00:07:59.918 And as we know in the last decade

NOTE Confidence: 0.8698586575

00:07:59.918 --> 00:08:02.035 15 years there have been a rush of

NOTE Confidence: 0.8698586575

00:08:02.035 --> 00:08:03.997 a series of different no acts that

NOTE Confidence: 0.8698586575

00:08:03.997 --> 00:08:05.964 have been used and proposed that have

NOTE Confidence: 0.8698586575

00:08:05.970 --> 00:08:08.098 different profiles for administration,

NOTE Confidence: 0.8698586575

00:08:08.098 --> 00:08:09.380 safety, efficacy etc.

NOTE Confidence: 0.8698586575

00:08:09.380 --> 00:08:12.890 At the time when we were proposing the trial,

NOTE Confidence: 0.8698586575

00:08:12.890 --> 00:08:14.318 of course apixaban.

NOTE Confidence: 0.8698586575

00:08:14.318 --> 00:08:18.220 Had the what we thought was the safe,

NOTE Confidence: 0.8698586575

00:08:18.220 --> 00:08:20.788 the best safety and efficacy profile,

NOTE Confidence: 0.8698586575

00:08:20.790 --> 00:08:22.764 and the best recommendation from the

NOTE Confidence: 0.8698586575

00:08:22.764 --> 00:08:24.429 American Heart Association for a FIB,

NOTE Confidence: 0.8698586575

00:08:24.430 --> 00:08:25.840 at least at the time,

NOTE Confidence: 0.8698586575

00:08:25.840 --> 00:08:28.234 and so that was a big part of it.

NOTE Confidence: 0.8698586575

00:08:28.240 --> 00:08:31.048 But there was another part of it too,  
NOTE Confidence: 0.8698586575

00:08:31.050 --> 00:08:33.437 which was that you know, this,  
NOTE Confidence: 0.8698586575

00:08:33.437 --> 00:08:35.459 uh, as we've heard earlier today,  
NOTE Confidence: 0.8698586575

00:08:35.460 --> 00:08:36.980 I think from Martin Landsberg,  
NOTE Confidence: 0.8698586575

00:08:36.980 --> 00:08:39.302 all of these trials cost a lot of money,  
NOTE Confidence: 0.8698586575

00:08:39.310 --> 00:08:41.782 and I think for those of you several  
NOTE Confidence: 0.8698586575

00:08:41.782 --> 00:08:43.574 on the call who are proposing trials,  
NOTE Confidence: 0.8698586575

00:08:43.580 --> 00:08:45.288 you know we're always trying to cut  
NOTE Confidence: 0.8698586575

00:08:45.288 --> 00:08:46.898 those costs as much as possible,  
NOTE Confidence: 0.8698586575

00:08:46.900 --> 00:08:49.114 and one of the places where there is a  
NOTE Confidence: 0.8698586575

00:08:49.114 --> 00:08:51.355 big ticket is in fact the study drug.  
NOTE Confidence: 0.8698586575

00:08:51.360 --> 00:08:52.158 In fact,  
NOTE Confidence: 0.8698586575

00:08:52.158 --> 00:08:55.350 you know when the Arcadia trial got funded,  
NOTE Confidence: 0.8698586575

00:08:55.350 --> 00:08:56.730 one of the things that really  
NOTE Confidence: 0.8698586575

00:08:56.730 --> 00:08:58.250 pushed them over the finish line.  
NOTE Confidence: 0.8698586575

00:08:58.250 --> 00:09:01.260 From the 80 to the A1 admission

NOTE Confidence: 0.8698586575

00:09:01.260 --> 00:09:03.828 submissions was the ability to get

NOTE Confidence: 0.8698586575

00:09:03.828 --> 00:09:06.610 the drug from Bristol Myers Squibb.

NOTE Confidence: 0.8698586575

00:09:06.610 --> 00:09:07.254 You know,

NOTE Confidence: 0.8698586575

00:09:07.254 --> 00:09:09.508 essentially at no cost or minimal cost,

NOTE Confidence: 0.8698586575

00:09:09.510 --> 00:09:12.355 you know to to the NINNINDS,

NOTE Confidence: 0.8698586575

00:09:12.355 --> 00:09:14.630 and this comes up all the time.

NOTE Confidence: 0.8698586575

00:09:14.630 --> 00:09:17.782 I'll tell you that we went around to

NOTE Confidence: 0.8698586575

00:09:17.782 --> 00:09:19.853 every manufacturer of know acts at

NOTE Confidence: 0.8698586575

00:09:19.853 --> 00:09:22.580 the time and asked them if they were

NOTE Confidence: 0.8698586575

00:09:22.580 --> 00:09:25.534 interested and you know it was interesting.

NOTE Confidence: 0.8698586575

00:09:25.540 --> 00:09:27.050 I mean, remember these patients

NOTE Confidence: 0.8698586575

00:09:27.050 --> 00:09:28.258 have been excluded from.

NOTE Confidence: 0.8698586575

00:09:28.260 --> 00:09:30.700 Every prior trial of anticoagulation

NOTE Confidence: 0.8698586575

00:09:30.700 --> 00:09:34.470 and not only were they not interested,

NOTE Confidence: 0.8698586575

00:09:34.470 --> 00:09:36.974 several of them told us look you use

NOTE Confidence: 0.8698586575

00:09:36.974 --> 00:09:40.185 our drug and you start to have safety events.

NOTE Confidence: 0.8698586575

00:09:40.190 --> 00:09:41.660 You know you may have lawsuits

NOTE Confidence: 0.8698586575

00:09:41.660 --> 00:09:42.960 on your hand as well,

NOTE Confidence: 0.8698586575

00:09:42.960 --> 00:09:45.159 you know so.

NOTE Confidence: 0.8698586575

00:09:45.160 --> 00:09:46.660 You know there's just a range

NOTE Confidence: 0.8698586575

00:09:46.660 --> 00:09:47.840 of considerations that come up.

NOTE Confidence: 0.8698586575

00:09:47.840 --> 00:09:49.610 I think when you're working with

NOTE Confidence: 0.8698586575

00:09:49.610 --> 00:09:50.200 different manufacturers,

NOTE Confidence: 0.8698586575

00:09:50.200 --> 00:09:51.608 different potential study drugs

NOTE Confidence: 0.8698586575

00:09:51.608 --> 00:09:54.347 and you know we we learned a lot

NOTE Confidence: 0.8698586575

00:09:54.347 --> 00:09:55.479 at those early stages,

NOTE Confidence: 0.8698586575

00:09:55.480 --> 00:09:58.840 so this is sort of what I mean by no

NOTE Confidence: 0.8698586575

00:09:58.938 --> 00:10:01.442 choice of drug and no free lunch.

NOTE Confidence: 0.8698586575

00:10:01.442 --> 00:10:01.990 You know,

NOTE Confidence: 0.8698586575

00:10:01.990 --> 00:10:04.654 a lot of different sort of

NOTE Confidence: 0.8698586575

00:10:04.654 --> 00:10:05.986 background background issues.

NOTE Confidence: 0.8698586575

00:10:05.990 --> 00:10:08.195 What when you end up supplying your

NOTE Confidence: 0.8698586575

00:10:08.195 --> 00:10:10.544 own drug and this was the first

NOTE Confidence: 0.8698586575

00:10:10.544 --> 00:10:12.548 time this had happened in stroke

NOTE Confidence: 0.896476471333333

00:10:12.623 --> 00:10:15.243 net where we had a trial that had it for

NOTE Confidence: 0.896476471333333

00:10:15.250 --> 00:10:17.994 a prevention trial that where we had to

NOTE Confidence: 0.896476471333333

00:10:17.994 --> 00:10:20.504 secure our own our own medication outside

NOTE Confidence: 0.896476471333333

00:10:20.504 --> 00:10:23.698 of a sponsor sort of providing it for us.

NOTE Confidence: 0.896476471333333

00:10:23.700 --> 00:10:26.340 Well, it raised all these other issues about.

NOTE Confidence: 0.896476471333333

00:10:26.340 --> 00:10:29.850 Well, if you're coming up with your own drug,

NOTE Confidence: 0.896476471333333

00:10:29.850 --> 00:10:31.712 how are you going to come up

NOTE Confidence: 0.896476471333333

00:10:31.712 --> 00:10:33.080 with your own placebo?

NOTE Confidence: 0.896476471333333

00:10:33.080 --> 00:10:36.184 And that meant how do you design it?

NOTE Confidence: 0.896476471333333

00:10:36.190 --> 00:10:39.718 How do you know how closely should

NOTE Confidence: 0.896476471333333

00:10:39.718 --> 00:10:42.349 resemble the actual study drug?

NOTE Confidence: 0.896476471333333

00:10:42.350 --> 00:10:45.257 You know when you get the drug from a

NOTE Confidence: 0.896476471333333

00:10:45.257 --> 00:10:48.118 sponsor, the sponsor owns the all the  
NOTE Confidence: 0.896476471333333

00:10:48.118 --> 00:10:50.946 trademarks to the drug so they can really,  
NOTE Confidence: 0.896476471333333

00:10:50.946 --> 00:10:52.650 truly make they're in a best  
NOTE Confidence: 0.896476471333333

00:10:52.715 --> 00:10:54.845 position to make a matching placebo.  
NOTE Confidence: 0.896476471333333

00:10:54.850 --> 00:10:58.000 When you go to a drug that still is not  
NOTE Confidence: 0.896476471333333

00:10:58.084 --> 00:11:01.477 off patent and you have to make a placebo,  
NOTE Confidence: 0.896476471333333

00:11:01.480 --> 00:11:05.038 there are issues come up about.  
NOTE Confidence: 0.896476471333333

00:11:05.040 --> 00:11:06.708 Patents and trademarks actually  
NOTE Confidence: 0.896476471333333

00:11:06.708 --> 00:11:08.894 so you have to, you know,  
NOTE Confidence: 0.896476471333333

00:11:08.894 --> 00:11:10.436 somehow thread the needle to be  
NOTE Confidence: 0.896476471333333

00:11:10.436 --> 00:11:12.268 able to get around those issues,  
NOTE Confidence: 0.896476471333333

00:11:12.270 --> 00:11:14.220 but also be able to provide  
NOTE Confidence: 0.896476471333333

00:11:14.220 --> 00:11:15.195 a matching placebo.  
NOTE Confidence: 0.896476471333333

00:11:15.200 --> 00:11:15.719 So those are.  
NOTE Confidence: 0.896476471333333

00:11:15.719 --> 00:11:16.930 Those are the kinds of things that  
NOTE Confidence: 0.896476471333333

00:11:16.966 --> 00:11:18.114 you know we had to work through,

NOTE Confidence: 0.896476471333333  
00:11:18.120 --> 00:11:20.680 sort of at the beginning.  
NOTE Confidence: 0.896476471333333  
00:11:20.680 --> 00:11:22.870 What about choice of endpoints and  
NOTE Confidence: 0.896476471333333  
00:11:22.870 --> 00:11:24.960 choice of population so you know,  
NOTE Confidence: 0.896476471333333  
00:11:24.960 --> 00:11:26.250 we found this to be really,  
NOTE Confidence: 0.896476471333333  
00:11:26.250 --> 00:11:26.756 really interesting,  
NOTE Confidence: 0.896476471333333  
00:11:26.756 --> 00:11:28.780 and I think something that a lot of  
NOTE Confidence: 0.896476471333333  
00:11:28.833 --> 00:11:30.537 folks here have a lot of interest in.  
NOTE Confidence: 0.896476471333333  
00:11:30.540 --> 00:11:34.540 You know some of the prelim data that we had,  
NOTE Confidence: 0.896476471333333  
00:11:34.540 --> 00:11:36.526 we and other groups have published  
NOTE Confidence: 0.896476471333333  
00:11:36.526 --> 00:11:39.210 really was. First of all, just codifying.  
NOTE Confidence: 0.896476471333333  
00:11:39.210 --> 00:11:41.185 What was I think essentially  
NOTE Confidence: 0.896476471333333  
00:11:41.185 --> 00:11:43.160 accepted sort of clinical question  
NOTE Confidence: 0.896476471333333  
00:11:43.229 --> 00:11:46.080 that it really wasn't sort of  
NOTE Confidence: 0.896476471333333  
00:11:46.080 --> 00:11:49.284 showing efficacy versus you know,  
NOTE Confidence: 0.896476471333333  
00:11:49.284 --> 00:11:50.626 a background.  
NOTE Confidence: 0.896476471333333

00:11:50.630 --> 00:11:53.190 There's an active comparator arm and  
NOTE Confidence: 0.896476471333333

00:11:53.190 --> 00:11:56.230 the other piece of that is that you're  
NOTE Confidence: 0.896476471333333

00:11:56.230 --> 00:11:59.240 trying to figure out the difference  
NOTE Confidence: 0.896476471333333

00:11:59.240 --> 00:12:01.276 between bleeding and clotting.  
NOTE Confidence: 0.896476471333333

00:12:01.280 --> 00:12:03.560 And so traditionally, again,  
NOTE Confidence: 0.896476471333333

00:12:03.560 --> 00:12:05.840 in stroke prevention trials,  
NOTE Confidence: 0.896476471333333

00:12:05.840 --> 00:12:08.820 hard clinical endpoints like clinical  
NOTE Confidence: 0.896476471333333

00:12:08.820 --> 00:12:12.660 events have been the main piece of  
NOTE Confidence: 0.896476471333333

00:12:12.660 --> 00:12:15.870 what's used for trial endpoints.  
NOTE Confidence: 0.896476471333333

00:12:15.870 --> 00:12:18.160 In a sick population like  
NOTE Confidence: 0.896476471333333

00:12:18.160 --> 00:12:19.534 brain hemorrhage survivors,  
NOTE Confidence: 0.896476471333333

00:12:19.540 --> 00:12:21.650 certainly mortality comes into play.  
NOTE Confidence: 0.896476471333333

00:12:21.650 --> 00:12:25.395 And we saw in our preliminary data  
NOTE Confidence: 0.896476471333333

00:12:25.395 --> 00:12:28.909 that even when you looked at not  
NOTE Confidence: 0.896476471333333

00:12:28.909 --> 00:12:32.419 low bar and non low bar patients  
NOTE Confidence: 0.896476471333333

00:12:32.419 --> 00:12:35.634 that you know certainly these

NOTE Confidence: 0.896476471333333

00:12:35.634 --> 00:12:38.138 endpoints were very important,

NOTE Confidence: 0.896476471333333

00:12:38.140 --> 00:12:39.304 but so was mortality.

NOTE Confidence: 0.896476471333333

00:12:39.304 --> 00:12:39.886 In fact,

NOTE Confidence: 0.896476471333333

00:12:39.890 --> 00:12:42.170 you can see that the association

NOTE Confidence: 0.896476471333333

00:12:42.170 --> 00:12:44.192 with a protective signal on

NOTE Confidence: 0.896476471333333

00:12:44.192 --> 00:12:46.357 mortality was actually quite robust.

NOTE Confidence: 0.896476471333333

00:12:46.360 --> 00:12:48.725 Acknowledging that all of these

NOTE Confidence: 0.896476471333333

00:12:48.725 --> 00:12:50.617 observation ull charities were

NOTE Confidence: 0.896476471333333

00:12:50.617 --> 00:12:52.820 likely highly confounded by

NOTE Confidence: 0.896476471333333

00:12:52.820 --> 00:12:55.270 virtue of their their design.

NOTE Confidence: 0.896476471333333

00:12:55.270 --> 00:12:57.769 And you can see the point estimates

NOTE Confidence: 0.896476471333333

00:12:57.769 --> 00:12:59.690 for ischemic stroke very strong.

NOTE Confidence: 0.896476471333333

00:12:59.690 --> 00:13:00.255 Also,

NOTE Confidence: 0.896476471333333

00:13:00.255 --> 00:13:03.645 like in prior studies of anticoagulation,

NOTE Confidence: 0.896476471333333

00:13:03.650 --> 00:13:05.442 but nevertheless not nearly

NOTE Confidence: 0.896476471333333

00:13:05.442 --> 00:13:07.234 as strong as mortality.  
NOTE Confidence: 0.896476471333333

00:13:07.240 --> 00:13:09.333 The other thing that you can see  
NOTE Confidence: 0.896476471333333

00:13:09.333 --> 00:13:11.567 that was quite strong was actually  
NOTE Confidence: 0.896476471333333

00:13:11.567 --> 00:13:13.677 the effect on functional outcome.  
NOTE Confidence: 0.896476471333333

00:13:13.680 --> 00:13:15.955 And we thought functional outcome  
NOTE Confidence: 0.896476471333333

00:13:15.955 --> 00:13:18.851 actually might be a really attractive  
NOTE Confidence: 0.896476471333333

00:13:18.851 --> 00:13:21.566 endpoint for a prevention study,  
NOTE Confidence: 0.896476471333333

00:13:21.570 --> 00:13:24.858 in part because it may have  
NOTE Confidence: 0.896476471333333

00:13:24.858 --> 00:13:26.502 more patient relevance.  
NOTE Confidence: 0.896476471333333

00:13:26.510 --> 00:13:29.612 You know functional outcome and it  
NOTE Confidence: 0.896476471333333

00:13:29.612 --> 00:13:32.635 is lesion and location naive, right?  
NOTE Confidence: 0.896476471333333

00:13:32.635 --> 00:13:34.210 We don't worry about whether  
NOTE Confidence: 0.896476471333333

00:13:34.210 --> 00:13:35.470 or not it's a  
NOTE Confidence: 0.852922882222222

00:13:35.542 --> 00:13:37.877 small hemorrhage versus a large  
NOTE Confidence: 0.852922882222222

00:13:37.877 --> 00:13:39.278 recurrent ischemic stroke.  
NOTE Confidence: 0.852922882222222

00:13:39.280 --> 00:13:41.008 And in some sense, maybe neither

NOTE Confidence: 0.852922882222222

00:13:41.008 --> 00:13:43.158 do patients what they care about is

NOTE Confidence: 0.852922882222222

00:13:43.158 --> 00:13:44.723 the disability that they're left.

NOTE Confidence: 0.852922882222222

00:13:44.730 --> 00:13:46.362 So I'll tell you in our

NOTE Confidence: 0.852922882222222

00:13:46.362 --> 00:13:47.730 initial application to the NIH,

NOTE Confidence: 0.852922882222222

00:13:47.730 --> 00:13:50.010 we actually proposed functional

NOTE Confidence: 0.852922882222222

00:13:50.010 --> 00:13:53.430 outcome MRSI as the primary endpoint

NOTE Confidence: 0.852922882222222

00:13:53.430 --> 00:13:55.830 and part of the feedback actually.

NOTE Confidence: 0.852922882222222

00:13:55.830 --> 00:13:58.646 Believe it or not from review was that

NOTE Confidence: 0.852922882222222

00:13:58.646 --> 00:14:01.338 funk that was thought to be sort of.

NOTE Confidence: 0.852922882222222

00:14:01.340 --> 00:14:02.318 Two different 22.

NOTE Confidence: 0.852922882222222

00:14:02.318 --> 00:14:05.453 I don't want to say two innovative but two

NOTE Confidence: 0.852922882222222

00:14:05.453 --> 00:14:07.805 different compared to prior stroke trials.

NOTE Confidence: 0.852922882222222

00:14:07.810 --> 00:14:10.470 So what we ended up doing is

NOTE Confidence: 0.852922882222222

00:14:10.470 --> 00:14:12.927 actually making it our key secondary

NOTE Confidence: 0.852922882222222

00:14:12.927 --> 00:14:15.811 and then reverting back to a more

NOTE Confidence: 0.852922882222222

00:14:15.896 --> 00:14:18.158 traditional stroke endpoint.  
NOTE Confidence: 0.8529228822222222

00:14:18.160 --> 00:14:19.994 I'll finally end in the last couple  
NOTE Confidence: 0.8529228822222222

00:14:19.994 --> 00:14:21.701 of minutes here and and just tell  
NOTE Confidence: 0.8529228822222222

00:14:21.701 --> 00:14:22.997 you as many of you know,  
NOTE Confidence: 0.8529228822222222

00:14:23.000 --> 00:14:24.674 there have been other trials that  
NOTE Confidence: 0.8529228822222222

00:14:24.674 --> 00:14:26.759 have been going on around the world.  
NOTE Confidence: 0.8529228822222222

00:14:26.760 --> 00:14:29.840 Other phase two and phase three type studies.  
NOTE Confidence: 0.8529228822222222

00:14:29.840 --> 00:14:31.484 This was one that was published  
NOTE Confidence: 0.8529228822222222

00:14:31.484 --> 00:14:33.130 just recently in Lancet Neurology,  
NOTE Confidence: 0.8529228822222222

00:14:33.130 --> 00:14:36.420 an open label RCT in the UK.  
NOTE Confidence: 0.8529228822222222

00:14:36.420 --> 00:14:38.676 Lots of similarities, lots of differences.  
NOTE Confidence: 0.8529228822222222

00:14:38.680 --> 00:14:41.158 There was an open label design  
NOTE Confidence: 0.8529228822222222

00:14:41.160 --> 00:14:43.036 they were looking at.  
NOTE Confidence: 0.8529228822222222

00:14:43.036 --> 00:14:45.381 Non inferiority of anticoagulation and  
NOTE Confidence: 0.8529228822222222

00:14:45.381 --> 00:14:48.569 the comparison group had either aspirin.  
NOTE Confidence: 0.8529228822222222

00:14:48.570 --> 00:14:51.630 Or no anti thrombotic.

NOTE Confidence: 0.852922882222222

00:14:51.630 --> 00:14:54.570 Ultimately they were underpowered

NOTE Confidence: 0.852922882222222

00:14:54.570 --> 00:14:58.980 to look at any efficacy endpoint.

NOTE Confidence: 0.852922882222222

00:14:58.980 --> 00:15:01.255 And they had a figure in their

NOTE Confidence: 0.852922882222222

00:15:01.255 --> 00:15:03.472 paper that showed the numerical

NOTE Confidence: 0.852922882222222

00:15:03.472 --> 00:15:05.820 differences between various endpoints,

NOTE Confidence: 0.852922882222222

00:15:05.820 --> 00:15:07.494 and I draw your attention away

NOTE Confidence: 0.852922882222222

00:15:07.494 --> 00:15:09.053 from the bleeding and clotting

NOTE Confidence: 0.852922882222222

00:15:09.053 --> 00:15:10.597 because we know ultimately,

NOTE Confidence: 0.852922882222222

00:15:10.600 --> 00:15:11.924 these were small numbers,

NOTE Confidence: 0.852922882222222

00:15:11.924 --> 00:15:13.579 none of which had significance,

NOTE Confidence: 0.852922882222222

00:15:13.580 --> 00:15:14.918 but something that we had been

NOTE Confidence: 0.852922882222222

00:15:14.918 --> 00:15:16.619 Penguin to a lot of attention to,

NOTE Confidence: 0.852922882222222

00:15:16.620 --> 00:15:18.426 and that we continue to do so.

NOTE Confidence: 0.852922882222222

00:15:18.430 --> 00:15:19.350 Which was that, you know,

NOTE Confidence: 0.852922882222222

00:15:19.350 --> 00:15:21.373 mortality was a part of our primary

NOTE Confidence: 0.852922882222222

00:15:21.373 --> 00:15:23.920 endpoint for a number of different reasons,

NOTE Confidence: 0.852922882222222

00:15:23.920 --> 00:15:26.954 including the strong effect size combined

NOTE Confidence: 0.852922882222222

00:15:26.954 --> 00:15:29.866 with the feasibility of what we needed to.

NOTE Confidence: 0.852922882222222

00:15:29.870 --> 00:15:32.005 To propose in order to get a

NOTE Confidence: 0.852922882222222

00:15:32.005 --> 00:15:33.938 study funded and to go forward.

NOTE Confidence: 0.852922882222222

00:15:33.940 --> 00:15:35.176 But you know,

NOTE Confidence: 0.852922882222222

00:15:35.176 --> 00:15:38.060 we're very mindful of the fact that

NOTE Confidence: 0.852922882222222

00:15:38.060 --> 00:15:40.444 all causes of death are not the same,

NOTE Confidence: 0.852922882222222

00:15:40.450 --> 00:15:42.730 and all of them may or may not

NOTE Confidence: 0.852922882222222

00:15:42.730 --> 00:15:44.669 be modified by anticoagulation.

NOTE Confidence: 0.852922882222222

00:15:44.670 --> 00:15:45.828 And I think you know this.

NOTE Confidence: 0.852922882222222

00:15:45.830 --> 00:15:48.410 This figure may support that.

NOTE Confidence: 0.852922882222222

00:15:48.410 --> 00:15:50.570 That's a potential concern going forward,

NOTE Confidence: 0.852922882222222

00:15:50.570 --> 00:15:53.041 so that's something that I think that

NOTE Confidence: 0.852922882222222

00:15:53.041 --> 00:15:55.457 will all continue to pay attention to.

NOTE Confidence: 0.852922882222222

00:15:55.460 --> 00:15:58.016 Those are some of the aspects that went into.

NOTE Confidence: 0.852922882222222

00:15:58.020 --> 00:16:01.800 Ultimately, what are our overall aspiring's,

NOTE Confidence: 0.852922882222222

00:16:01.800 --> 00:16:02.600 which I think you know,

NOTE Confidence: 0.852922882222222

00:16:02.600 --> 00:16:04.656 which is to really look to see if

NOTE Confidence: 0.852922882222222

00:16:04.656 --> 00:16:06.589 apixaban is superior or aspirin in

NOTE Confidence: 0.852922882222222

00:16:06.589 --> 00:16:08.617 a double blind design on traditional

NOTE Confidence: 0.852922882222222

00:16:08.676 --> 00:16:09.650 stroke endpoints.

NOTE Confidence: 0.852922882222222

00:16:09.650 --> 00:16:12.134 But we are going to pay a lot of

NOTE Confidence: 0.852922882222222

00:16:12.134 --> 00:16:14.052 attention to outcomes like the

NOTE Confidence: 0.852922882222222

00:16:14.052 --> 00:16:16.416 modified Rankin and and other outcomes.

NOTE Confidence: 0.852922882222222

00:16:16.420 --> 00:16:17.890 The overall design.

NOTE Confidence: 0.852922882222222

00:16:17.890 --> 00:16:20.830 I think everyone is familiar with

NOTE Confidence: 0.852922882222222

00:16:20.830 --> 00:16:21.574 and you know,

NOTE Confidence: 0.852922882222222

00:16:21.574 --> 00:16:24.099 for those of you who are on the call

NOTE Confidence: 0.852922882222222

00:16:24.099 --> 00:16:26.277 where we've launched this one campaign.

NOTE Confidence: 0.852922882222222

00:16:26.280 --> 00:16:28.926 And in honor of U2 and Bono,

NOTE Confidence: 0.852922882222222

00:16:28.930 --> 00:16:30.764 for those of you who are from  
NOTE Confidence: 0.852922882222222

00:16:30.764 --> 00:16:32.295 that generation, and you know,  
NOTE Confidence: 0.852922882222222

00:16:32.295 --> 00:16:33.970 we're hoping every center will  
NOTE Confidence: 0.852922882222222

00:16:33.970 --> 00:16:35.938 be able to just put in one.  
NOTE Confidence: 0.852922882222222

00:16:35.940 --> 00:16:37.840 So I I think I'm towards the end of my  
NOTE Confidence: 0.940449036363636

00:16:37.899 --> 00:16:39.530 time. But if there's time for  
NOTE Confidence: 0.940449036363636

00:16:39.530 --> 00:16:40.742 questions, I'd be happy to  
NOTE Confidence: 0.940449036363636

00:16:40.742 --> 00:16:42.140 answer any that you might have.  
NOTE Confidence: 0.935263896

00:16:44.470 --> 00:16:47.634 Thank you so much Kevin. I don't  
NOTE Confidence: 0.935263896

00:16:47.634 --> 00:16:50.540 see any questions in the chat box.  
NOTE Confidence: 0.925793401428571

00:16:53.810 --> 00:16:57.176 I think if anyone has any questions please  
NOTE Confidence: 0.925793401428571

00:16:57.176 --> 00:17:00.020 type them in the chat box or feel free  
NOTE Confidence: 0.925793401428571

00:17:00.097 --> 00:17:02.629 to reach out Doctor Chat afterwards.  
NOTE Confidence: 0.925793401428571

00:17:02.630 --> 00:17:05.762 I think for the interest of time it's 115.  
NOTE Confidence: 0.925793401428571

00:17:05.770 --> 00:17:08.994 I will move on to the next speaker.